Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.
Jennifer Kim, PharmD
Advertisement
Articles by Jennifer Kim, PharmD
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
3
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
4
ATTR-CM Incidence, Prevalence Rose Sharply in the US
5